Resilient argenx stock trades above €780 as biotech valuation climbs

Argenx stock holds well above €780 and a $65 billion valuation as investors weigh recent revenue growth and margins against ambitious biotech expectations.

Argenx SE (ISIN NL0010832176) stock continues to trade at a high valuation in late August 2026, with the shares quoted at €781.80 on the Belgian market as of August 24, 2026 according to a recent large-cap overview. That pricing level supports a market capitalization of €48.6 billion and reflects a 63.5 percent share price gain over the past year, underscoring how strongly the stock has performed in the European pharmaceuticals and biotech segment.

High valuation backed by growth metrics

The same Belgian large-cap overview shows that, at a last price of €781.80 on August 24, 2026, argenx is among the largest names in its domestic market, with a €48.6 billion market cap and a growth score that points to expected expansion of around 21.5 percent. For investors, this combination of scale and projected growth helps justify a premium valuation in a sector where clinical progress and commercial execution are closely watched.

On the Nasdaq, a separate market-cap listing reports argenx with a share price of $1,039.78 and a market capitalization of $65.03 billion, illustrating the company’s substantial size in the global biotech universe. The same data set lists EBITDA at $2.03 billion and a price-to-earnings multiple of 32.97 times, together with a debt-to-equity ratio of 0.19, showing that the company pairs significant profitability with relatively modest leverage compared with many peers.

Analyst targets and performance comparison

The Belgian overview adds that analysts there have set a consensus target of €869.07 for argenx as of August 24, 2026, which is 11.1 percent above the current €781.80 trading level. That spread indicates that professional forecasts still point to further upside from today’s price even after the stock’s 63.5 percent gain over the last twelve months, suggesting that the growth story is not yet fully priced in according to the available data.

Relating the Nasdaq valuation metrics to the European price picture reinforces the premium nature of argenx stock. A P/E of 32.97 times paired with EBITDA of $2.03 billion implies that investors are willing to pay a high multiple for the company’s earnings and cash generation, likely reflecting confidence in ongoing revenue expansion and a pipeline that can support future margins. The low debt-to-equity ratio of 0.19 further supports the thesis that the balance sheet can sustain continued investment without excessive financial risk.

Key product underpins biotech narrative

Argenx’s business is built around antibody-based therapies designed to treat severe autoimmune diseases and other difficult conditions, and a leading product in this portfolio has become central to the company’s recent revenue trajectory. This flagship therapy targets specific mechanisms in the immune system and has secured approvals in multiple markets, creating a recurring revenue stream that supports the strong EBITDA figure cited in recent market-cap data.

Beyond this lead product, argenx continues to develop additional candidates using its antibody platform, aiming to broaden its portfolio and deepen its presence across autoimmune and related indications. The growth expectations of 21.5 percent referenced in the Belgian data set align with a strategy that depends on both expanding indications for existing therapies and bringing new drugs to market over time.

Stock level and investor takeaway

With argenx stock at €781.80 as of August 24, 2026 on the Belgian market and a parallel Nasdaq quote of $1,039.78, the company commands a market capitalization of €48.6 billion in Europe and $65.03 billion in the United States based on current data. That valuation, supported by EBITDA of $2.03 billion, a P/E of 32.97 times, a debt-to-equity ratio of 0.19, and analysts’ €869.07 target, positions argenx as a major biotech name where share performance has been strong but where earnings and pipeline execution remain critical for sustaining the premium pricing.

Read more

Further details on argenx’s investor communications are available on the company’s own investor pages, which provide access to presentations, filings, and updates on its antibody-based drug portfolio and financial outlook.

Fact box

Company: Argenx SE

ISIN: NL0010832176

Ticker: ARGX

Exchange: Euronext Brussels and Nasdaq

Price (as of August 24, 2026): €781.80 on Euronext Brussels; $1,039.78 on Nasdaq

Market cap: €48.6 billion in Belgium; $65.03 billion based on Nasdaq data

Sector / Industry: Pharmaceuticals and biotechnology

Index membership: Included among large Belgian stocks tracked alongside BEL20 constituents